GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Cash Flow from Financing

Gilead Sciences (BUE:GILD) Cash Flow from Financing : ARS-5,498,532 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2024, Gilead Sciences paid ARS192,001 Mil more to buy back shares than it received from issuing new shares. It spent ARS106,456 Mil paying down its debt. It paid ARS0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent ARS934,341 Mil paying cash dividends to shareholders. It spent ARS77,941 Mil on other financial activities. In all, Gilead Sciences spent ARS1,310,739 Mil on financial activities for the three months ended in Sep. 2024.


Gilead Sciences Cash Flow from Financing Historical Data

The historical data trend for Gilead Sciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cash Flow from Financing Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -456,311.66 62,662.60 -896,488.21 -1,084,527.82 -1,850,125.00

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -531,574.07 -396,739.00 -1,146,642.52 -2,644,411.46 -1,310,739.44

Gilead Sciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Gilead Sciences's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Flow from Financing(A: Dec. 2023 )
=Issuance of Stock+Repurchase of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=83752+-361000+-97470+0+-1375049.001+-100358.001
=-1,850,125

Gilead Sciences's Cash from Financing for the quarter that ended in Sep. 2024 is:

Cash Flow from Financing(Q: Sep. 2024 )
=Issuance of Stock+Repurchase of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=93148.996+-285149.987+-106455.995+0+-934341.459+-77940.997
=-1,310,739

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-5,498,532 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (BUE:GILD) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Gilead Sciences's issuance of stock for the three months ended in Sep. 2024 was ARS93,149 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Gilead Sciences's repurchase of stock for the three months ended in Sep. 2024 was ARS-285,150 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Gilead Sciences's net issuance of debt for the three months ended in Sep. 2024 was ARS-106,456 Mil. Gilead Sciences spent ARS106,456 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Gilead Sciences's net issuance of preferred for the three months ended in Sep. 2024 was ARS0 Mil. Gilead Sciences paid ARS0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Gilead Sciences's cash flow for dividends for the three months ended in Sep. 2024 was ARS-934,341 Mil. Gilead Sciences spent ARS934,341 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Gilead Sciences's other financing for the three months ended in Sep. 2024 was ARS-77,941 Mil. Gilead Sciences spent ARS77,941 Mil on other financial activities.


Gilead Sciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).